SEQUOIA added the immune cytokine pegilodecakin to second-line FOLFOX chemotherapy for pancreatic cancer and found no gain in survival, progression or response, another negative test of immunotherapy in this cold tumour.
SEQUOIA randomised 567 patients between March 2017 and September 2019 (283 to pegilodecakin plus FOLFOX, 284 to FOLFOX), 94.7 percent of whom had received gemcitabine plus nab-paclitaxel. Median overall survival was 5.8 against 6.3 months (hazard ratio 1.045, 95 percent confidence interval 0.863 to 1.265), progression-free survival 2.1 months in both arms and response 4.6 against 5.6 percent. Thrombocytopenia (55 against 20 percent) and anaemia (40 against 16) were commoner with the cytokine while interleukin-18, interferon gamma and granzyme B rose as expected. Five UK sites took part (Addenbrooke's, Hammersmith, Velindre, University College London Hospitals, Guy's and St Thomas'). The FOLFOX control arm's 6.3 months is a useful benchmark for second-line chemotherapy in the gemcitabine-nab-paclitaxel era.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
The full inclusion and exclusion criteria are on the registry record. Read 2026-11-17. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares Pancreatic cancer: the failed and stopped programmes and why, FOLFOX (5-FU, leucovorin, oxaliplatin), Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares Pancreatic cancer: the failed and stopped programmes and why, Hot vs cold tumours, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares Hot vs cold tumours, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/